Welcome to our dedicated page for JOINT SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
The Joint Corp. reported higher profitability while advancing its shift to a franchise‑focused model for the quarter and six months ended June 30, 2026. Continuing‑operations revenue reached $15.2 million for the quarter and $30.0 million year‑to‑date, driven mainly by royalty, advertising and software fees.
Continuing operations produced a quarterly net loss of $0.3 million but year‑to‑date net income of $0.9 million, while discontinued corporate clinics added $1.1 million of net income, bringing total net income to $2.0 million and diluted EPS of $0.14 for the first half of 2026.
The company continued refranchising its corporate clinics, ending the period with 896 franchised and 45 company‑owned or managed clinics, and assets held for sale of $12.3 million. Liquidity remained solid with $23.8 million in cash, cash equivalents and restricted cash, no borrowings outstanding under its credit facility, and share repurchases totaling $1.8 million year‑to‑date.
The Joint Corp., a chiropractic clinic franchisor, reported second quarter 2026 results reflecting its shift to a capital-light, pure-play franchisor model. Revenue from continuing operations was $15.2 million, up 14% year over year, while reported system-wide sales were $180.0 million, down 3.7%, and comp sales were (2.8)%.
Consolidated net income increased to $653,000 and net loss from continuing operations narrowed to $251,000 compared with a $1.0 million loss a year earlier. Adjusted EBITDA from continuing operations rose to $1.5 million from $88,000. Cash flow from operating activities improved to $2.2 million and free cash flow to $1.9 million.
The network had 941 clinics at June 30, 2026, reflecting openings, closures and refranchising under the Joint 2.0 strategy. Unrestricted cash totaled $22.2 million, and the company has an undrawn $20 million credit line. Management reaffirmed 2026 guidance, including system-wide sales of $519–$552 million, system-wide comp sales between (3)% and 3%, and consolidated Adjusted EBITDA of $12.5–$13.5 million.
BlackRock, Inc. reports its position in JOINT Corp common stock on a Schedule 13G/A. BlackRock and certain of its business units beneficially own 267,616 shares, representing 1.9% of the outstanding common stock as of June 30, 2026.
BlackRock has sole voting and sole dispositive power over all 267,616 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of JOINT Corp’s outstanding common shares.
JOINT Corp’s Chief Financial Officer, Scott Justin Bowman, reported a routine tax-withholding transaction involving company stock. On June 10, 2026, 1,392 shares of common stock were withheld at $8.43 per share to cover tax obligations tied to vesting restricted stock. Following this non-market transaction, he directly holds 46,893 shares of common stock.
Pant Milind reported acquisition or exercise transactions in this Form 4 filing.
The Joint Corp director Pant Milind received a stock grant reported on Form 4. He was awarded 5,714 shares of Common Stock as a grant or award, rather than an open-market purchase or sale, and now directly holds 5,714 shares.
All of these shares are restricted and will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of The Joint Corp’s stockholders, making this a standard equity compensation award tied to future service.
JOINT Corp director Milind Pant filed an initial ownership report showing no current holdings of the company’s stock. The Form 3 indicates that, as of the reported date, no securities of JOINT Corp are beneficially owned, and total direct holdings are listed as zero shares.
Karrmann Sandra R reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp director Sandra R. Karrmann received a grant of 5,714 shares of restricted common stock, with no cash paid per share. These restricted shares vest in full on the earlier of May 20, 2027 or the next annual meeting of stockholders. Following this award, she directly holds 10,563 common shares.
Grandpre Christopher M reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp director Christopher M. Grandpre received an equity grant of 5,714 shares of Common Stock. The award was granted at no cash cost as restricted shares. All 5,714 shares vest in full on the earlier of May 20, 2027 or the next annual meeting of JOINT Corp stockholders. Following this grant, Grandpre directly holds a total of 45,097 Common Stock shares, reflecting a routine stock-based compensation award rather than an open-market purchase or sale.
Joint Corp director Ronald V. DaVella received an equity award of 5,714 shares of Common Stock. These shares are restricted and were granted at no purchase price. They will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of the stockholders of The Joint Corp.
After this grant, DaVella directly holds a total of 23,243 Joint Corp common shares. As a grant/award acquisition, this is a compensation-related transaction rather than an open-market trade.
JOINT Corp director Matthew E. Rubel received a grant of 5,714 shares of Common Stock as compensation. The shares were acquired at a stated price of $0.00 per share and increase his direct holdings to 23,177 shares following the transaction. All of the granted shares are restricted and will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of the stockholders of The Joint Corp.